**Clinical Study**

**Hypothalamus-Anchored Resting Brain Network Changes before and after Sertraline Treatment in Major Depression**

Rui Yang,1,2,3 Hongbo Zhang,2,4 Xiaoping Wu,1,3 Junle Yang,1,3 Mingyue Ma,1,3 Yanjun Gao,1,3 Hongsheng Liu,1,3 and Shengbin Li2,4

1 The Affiliated Xi'an Central Hospital of Medical College of Xi'an Jiaotong University, Xi'an 710003, China
2 Key Laboratory of Environment and Gene Related Diseases, Ministry of Education, Xi'an Jiaotong University, Xi'an 710061, China
3 Xi'an Central Hospital, Xi'an 710003, China
4 Key Laboratory of Health Ministry for Forensic Science, Xi'an Jiaotong University, Xi'an 710061, China

Correspondence should be addressed to Shengbin Li; forensicslee@163.com

Received 26 January 2014; Revised 12 February 2014; Accepted 13 February 2014; Published 20 March 2014

Academic Editor: Lijun Bai

Copyright © 2014 Rui Yang et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Sertraline, one of the oldest antidepressants, remains to be the most efficacious treatment for depression. However, major depression disorder (MDD) is characterized by altered emotion processing and deficits in cognitive control. In cognitive interference tasks, patients with MDD have shown excessive hypothalamus activity. The purpose of this study was to examine the effects of antidepressant treatment (sertraline) on hypothalamus-anchored resting brain circuitry. Functional magnetic resonance imaging was conducted on depressed patients \( n = 12 \) both before and after antidepressant treatment. After eight weeks of antidepressant treatment, patients with depression showed significantly increased connectivity between the hypothalamus and dorsolateral prefrontal cortex, orbitofrontal cortex, anterior cingulate cortex, insula, putamen, caudate, and claustrum. By contrast, decreased connectivity of the hypothalamus-related areas was primarily located in the inferior frontal gyrus, medial frontal gyrus, cingulated gyrus, precuneus, thalamus, and cerebellum. After eight weeks of antidepressant therapy, 8 out of the 12 depressed subjects achieved 70% reduction or better in depressive symptoms, as measured on the Hamilton depression rating scale. Our findings may infer that antidepressant treatment can alter the functional connectivity of the hypothalamus resting brain to achieve its therapeutic effect.

1. Introduction

Depression is the commonest psychiatric disorder. It is the most disabling medical condition, in terms of years lost to disability, and it is predicted that depression will be the foremost contributor to the worldwide burden of disease by 2030 [1]. Depression is characterized by a profoundly negative view of the world, oneself, and the future [2], and this negative world view has been associated with negative biases in attention, interpretation, and memory [3]. In clinical settings, the depression is often misdiagnosed especially without a history of mania [4], leading to inadequate treatment, increased medical costs, and poor outcomes [5–7]. A recent upsurge of interest has been directed toward developing both diagnostic and prognostic biomarkers that can aid to diagnose which individuals are relatively more likely to progress clinically. Previous studies using structural MRI have already revealed abnormalities in various brain areas and significant changes in the amygdala volume in adults suffering from depression and mood disorders [8]. The affective network largely consists of the prefrontal cortex as well as subcortical and allocortical brain structures such as the thalamus, amygdala, basal ganglia, and hippocampus. Studies probing this system demonstrated reduced frontal-subcortical connectivity in depression [9], which is thought to reflect impaired cognitive regulation of mood. Therefore, in particular functional MRI (fMRI), studies of the neural mechanisms of depression have shifted from those highlighting focal regions of abnormal brain functions to those focusing on the dysfunctional brain connectivity between spatially distinct brain regions. Resting state fMRI reflects the neuronal baseline activity of the brain, representing the state of the human...
brain without goal-directed neuronal action and external input [10], and the resting state functional connectivity in the blood oxygenation level-dependent signal during rest corresponds to consistent functionally relevant resting state networks (RSNs) [11]. With the benefit of its easy control and good acceptance, the resting state fMRI has received increasing attention for studying unipolar depression [12]. Some previous studies have observed increased connectivity within the default mode (DMN) network in depressed patients, and, interestingly, heightened DMN connectivity is also associated with depressive ruminative [13, 14].

The hypothalamus is a subcortical region with roughly 4 cm³ neuronal tissue in human brain [15] located at the third ventricle, rostroventral to the thalamus. It consisted of several subareas embedded cytoarchitectonically distinguishable and proved to be functionally distinct with some functional overlaps [16]. Previous studies have demonstrated the involvement of hypothalamic nuclei in wide range of tasks including cognitive, behavioural, and visceral processes [17–21]. The hypothalamo-pituitary-adrenal (HPA) system constructs a common pathway in the mediation of the stress response. Cortisol normally exerts a negative feedback to shut down the stress response when facing the threat, acting upon the levels of the pituitary and hypothalamus. In addition, stimulation by corticosteroids can be exerted at the level of the amygdala, the prefrontal cortex, and the brain stem (locus coeruleus), interfering with HPA activity and stress effects on memory [22–24]. A large part of the environmental and genetic risk factors for depression appear to correlate with increased HPA-axis activity in adulthood. When patients or animals in models for depression are treated with antidepressants and electroconvulsive therapy or when patients show spontaneous remission, the HPA-axis function returns to normal [25]. Although antidepressant agents have been largely used for the treatment of major depressive disorder (MDD), the neurobiological mechanisms of their efficacy remains poorly understood [26–30]. Moreover, patients often present different clinical results: patients with fewer depressive episodes can achieve a rapid remission while others present with prolonged, remittent, or refractory illness [31–34]. In this respect, evaluating the brain functional antidepressant effects will allow a better understanding of the pathogenesis of MDD and its response to antidepressant treatment.

In the present study, we aimed to explore the effects of antidepressant treatment (sertraline) on functional connectivity in unipolar depression while using the hypothalamus as the seed region. To address this question, we conducted a functional magnetic resonance imaging study of depression patients both before and after antidepressant treatment while they performed a resting scanning. We hypothesized that depression patients after medication would present increased, relative to their premedicated state.

2. Materials and Methods

2.1. Patients. Twelve major depression patients (7 males) participated in this study. This study was conducted at Xi’an Central Hospital. Each subject underwent a screening evaluation involving structured clinical interviews and assessments by trained clinicians and semistructured medical and psychiatric interviews with the study psychiatrist (K.L.P.). All subjects were characterized with the (1) structured clinical interview for DSM-IV; (2) Hamilton depression rating scale (HDRS). Table 1 details the demographic and clinical characteristics of the subjects. All subjects had no history of head injury, organic mental disorders, alcohol or drug abuse, serious physical illness, or other mental illness. During the treatment, they were free of other treatments with psychiatric medications. None of the females were currently pregnant or lactating. All subjects provided written informed consent, and the study was approved by both local hospital institutional review boards. Head structural magnetic resonance imaging (MRI) results were evaluated by a single neuroimaging physician who was blinded to the experimental groups, and no obvious structural abnormalities were found.

2.2. Sertraline Treatment. Treatment consisted of the sertraline in a fixed-dosing design over 8 weeks (50–100 mg/day). Patients were evaluated at weeks 1 and 8 by the study psychiatrist (K.L.P.) in medication management sessions to assess symptom change and adverse events, with the target dose of 50–100 mg/day; clinical response was measured with the HDRS. Although we did not measure sertraline blood levels, the study psychiatrist and staff inquired about missed doses and conducted a pill count to confirm the subject report. No subject in the study ever missed more than 2 consecutive daily doses over the course of the 8-week study, and no subject regularly (>3 times) missed the dose.

Table I: Demographic and clinical characteristics of the subjects.

|                         | Depression group | Mean     | SD       |
|-------------------------|------------------|----------|----------|
| Age (years)             |                  | 34.91    | 12.16    |
| Duration (years)        |                  | 4.04     | 3.14     |
| Height (cm)             |                  | 168.3    | 6.54     |
| Weight (kg)             |                  | 79.51    | 9.96     |
| Hamilton depression (before) |             | 24.08    | 4.40     |
| Hamilton depression (after) |             | 5.83     | 2.32     |

2.3. Data Acquisition. The MR images were acquired with a 1.5 Tesla GE Excite MRI system (GE Health care Milwaukee, WI, USA). A foam pillow and a band across the forehead were used to fix the head. Resting state functional images were acquired with a single shot gradient recalled echo planar imaging sequence. The sequence covered the whole brain, axial view, parallel to the to the AC-PC line collected to cover the whole brain.

In AC-PC line, TR = 2500 ms, TE = 35 ms, resolution = 64 × 64, field of view (FOV) = 240 mm × 240 mm, flip angle = 90°, slice thickness = 3 mm without gap, 36 slices. A set of T1-weighted high-resolution structural images were collected using a 3D Fast SPGR sequence for anatomical localization.
Figure 1: Both the increased and decreased hypothalamus-related functional connectivity resting brain networks after 8-week sertraline treatment for major depression ($P < 0.01$, FDR corrected).

TR = 10.6 ms, TE = 4.8 ms, field of view (FOV) = 256 mm × 256 mm, flip angle = 15°, in-plane resolution = 1 mm × 1 mm, slice thickness: 1 mm without gap, 128 slices. All subjects were asked to remain relaxed without being engaged in any mental tasks. They were also instructed to keep their eyes closed but not fell asleep.

2.4. Image Preprocessing. All preprocessing steps were carried out using statistical parametric mapping (SPM5, http://www.fil.ion.ucl.ac.uk/spm/). Functional images were preprocessed using sinc interpolation for slice scan time correction, trilinear sinc interpolation for alignment (motion correction) of functional volumes, and high-pass temporal filtering to 1 Hz to remove slow drifts in the data. The image data were further processed with spatial normalization based on the MNI space and resampled at 2 mm × 2 mm × 2 mm. Resting data were also filtered using a band pass filter (0.01–0.08 Hz) to reduce low-frequency drift and high-frequency noise. Finally, the functional images were spatially smoothed with a 6 mm full width at half maximum (FWHM) Gaussian kernel. All resting state functional images were preprocessed using statistical parametric mapping 5 (SPM5) and included motion correction, normalization, and smoothing.

2.5. Functional Connectivity Analysis. For each subject, the “seeding” time courses of the hypothalamus were, respectively, cross-correlated with all low-pass filtered voxels to generate functional connectivity maps within each of the three conditions. The resulting correlation coefficient t-maps were normalized and corrected to roughly standard normal distributions using methods previously described. The normality of the distribution was then tested using Kurtosis tests ($P < 0.001$, corrected). The maps of each individual were entered into one-sample t-tests, respectively, to determine whether group data was significantly different from zero. For visualization, all connectivity results were transformed into the Talairach stereotactic space and overlaid on MRIcro (http://www.mccauslandcenter.sc.edu/CRNL/) for presentation purposes. All resulting t-maps were then cluster-filtered to remove correlations involving less than three contiguous voxels and then superimposed on high-resolution anatomical images using a $P < 0.001$ cut-off threshold (FDR, corrected).

3. Results

Due to excessive head movement during scanning, imaging data from 2 patients were excluded and consequently a total of 10 participants were included in this study. Their demographic data and psychological scores are listed in Table 1. After eight weeks of antidepressant therapy, 8 out of the 12 depressed subjects achieved 70% reduction or better in depressive symptoms, as measured on the HDRS scale. Seven showed 50–70% improvement, and the remaining four showed 59–68% reductions. Thus, in our sample, approximately two-third of the sample showed very significant improvements in symptoms, and all patients responded at least partially to the treatment.

Our results show that sertraline treatment has a larger impact on the hypothalamus-related brain networks for major depression patients (shown in Figure 1 and Table 2, $P < 0.005$, FWE corrected). After treatment, the hypothalamus
The major finding of this study is that sertraline treatment exhibited larger impacts on the modulation of the hypothalamus-related functional connectivity brain network for major depression patients. These associations may be partially verified by the promotion of depression degree. As expected, depression degree showed significant differences after sertraline treatment. Our findings contribute to the growing evidence that sertraline treatment may be a beneficial effect on the depression patients and it mainly involved prefrontal-limbic-hypothalamus pathways. To our knowledge, this is the first in vivo magnetic resonance imaging study to demonstrate sertraline treatment impact on the hypothalamus-related resting brain network in depression patients.

Major depressive disorder is characterized by disruptions in executive control, linked to abnormal DLPFC function. The DLPFC plays an important role in working memory and other aspects of executive function [35, 36]. Previous studies have demonstrated structural changes in the prefrontal regions in major depressive disorder subjects, including decreases in cortical thickness and neural size, together with reductions in neural and glial density [37]. In the study by Thomas et al., ischemia in the white matter of DLPFC was found in subjects with late-life depression [38] and lends support to the “vascular depression” hypothesis [39, 40]. Results from these studies associate depression with abnormally low levels of DLPFC activity [41, 42]. Our findings were consistent with studies linking the DLPFC with depression and further proved that sertraline treatment can effectively improve the functional connectivity between hypothalamus and DLPFC.

The major physiological response to stress involves activations of neuroendocrine systems, mainly through the hypothalamus-pituitary-adrenal (HPA) axis. Emotional stimuli always reach the HPA axis via the amygdala and descending pathways from the forebrain. The amygdala exerts excitatory control over the hypothalamus to stimulate the HPA axis, which, via increased cortisol levels, acts in a positive feedback manner to further stimulate

![Image of the table](https://via.placeholder.com/150)

| (a) Increased | Talairach | $t$ value | Voxels |
|--------------|-----------|-----------|--------|
| Frontal      |           |           |        |
| DLPFC BA/44  | R 48 16   | 3.08      | 44     |
| OFC BA/10    | R 8 38    | 2.25      | 44     |
| SFG BA/8     | R 14 39   | 2.33      | 22     |
| Precentral gyrus BA/44 | R 44 12 | 3.20 | 20 |
| Limbic       |           |           |        |
| ACC BA/24    | R 6 31    | 2.76      | 45     |
| Hippocampus  | R 33 -14  | 3.23      | 16     |
| Subcortical  |           |           |        |
| Insula BA/13 | R 42 12   | 2.61      | 43     |
| Putamen      | R 24 8    | 2.09      | 28     |
| Caudate      | R 8 10    | 3.57      | 82     |
| Claustrum    | R 32 -3   | 2.54      | 25     |
| Temporal     |           |           |        |
| STG BA/22    | R 63 -40  | 2.37      | 27     |
| Parietal     |           |           |        |
| IPL BA/40    | R 55 -44  | 2.40      | 38     |
| SG BA/40     | R 57 -37  | 2.33      | 24     |

| (b) Decreased | Talairach | $t$ value | Voxels |
|---------------|-----------|-----------|--------|
| Frontal       |           |           |        |
| IFG BA 47     | L 53 17   | -2.87     | 54     |
| IFG BA 9      | R -53 11  | -2.35     | 427    |
| Precentral gyrus | L -49 -8 | -2.29     | 16     |
| MFC BA 6/8    | R 6 -1    | -2.98     | 144    |
| SFG BA 6      | L -2 28   | -2.86     | 112    |
| Limbic        |           |           |        |
| Cingulate gyrus | L -6 6   | -2.63     | 155    |
| BA 32         | R 4 10    | -2.32     | 88     |
| Temporal cortex | L -53 -66 | -2.48     | 48     |
| MTL BA/37     | R -4 73   | -2.68     | 137    |
| Parietal cortex | BA 7 | R -4 44   | -2.19  | 37     |
| Thalamic      | L -4 4    | -2.34     | 30     |
| Cerebellum    | L -16 -82 | -3.46     | 455    |
| Declive       | R 36 -75  | -3.07     | 290    |
| Uvula         | L -28 -71 | -3.19     | 111    |
|               | R 34 -63  | -3.24     | 110    |

Abbreviations: BA: Brodmann area; DLPFC: dorsolateral prefrontal cortex; OFC: orbitofrontal cortex; SFG: superior frontal gyrus; ACC: anterior cingulate cortex; STG: superior temporal gyrus; IPL: inferior parietal lobule; MFC: medial frontal cortex; MTG: middle temporal gyrus; MTL: medial temporal lobe; Claustrum: claustrum; Temporal: middle temporal gyrus; Subcortical: insula, putamen, caudate, and claustrum; Parietal: inferior parietal lobule; Thalamic: thalamus; Cerebellum: declive and uvula.
the amygdala [43]. By contrast, the hippocampus exerts inhibitory control over the HPA axis, and hippocampus acts in a negative feedback manner to inhibit the HPA axis. This is crucial for limiting the activity of the HPA axis, since that, without it, the positive feedback loop via the amygdala would cause the system to run out of control [44–46]. Descending negative feedback over the HPA axis is also exerted at the level of the dorsomedial prefrontal cortex (PFC) and the prelimbic cortex [47] so activation of these areas by emotional self-regulation can also improve the control over the HPA axis. Our results were consistent with the inference that sertraline treatment can effectively improve the functional connectivity between the hypothalamus and hippocampus.

The functional role of the cingulate cortex—and specifically the ACC—in depression is well described [48]. Our data shows significant enhancement of functional connectivity between the hypothalamus and ACC. This region is also a key component of the default mode network [49]. Abnormal resting state functional connectivity of these same regions has been described in depression [13]. Previous work using DTI data shows that connectivity in the cingulate portion of the cingulate bundle has structural changes with depression at baseline and also has an impact on remission [50]. The OFC has extensive connections with the limbic system, including the cingulate cortex [51]. The presence of enhanced functional connectivity with the hypothalamus in both ACC and the OFC supports the notion that sertraline treatment can improve the damages on these regions.

Another intriguing research is the decreased functional connectivity between the hypothalamus and cerebellum (located in the posterior part). The cerebellum generally accepts the information from temporal lobe, prefrontal lobe, and cinguled gyrus and these areas have exerted controls on the cognitive and emotional regulation [52]. It is also emphasized that the involvement of the cerebellum in cognitive and emotional controls and proposed the concept of the cerebellar cognitive affective syndrome, which usually refers from the affective bluntness and depression to affective disorder, and finally appears in execution, visual, spatial and language dysfunction [53]. Our results proved that the hypothalamus may project attenuated influence on the cerebellum after the sertraline treatment.

Limitations of this study include potential bias given that only small samples were included in the current study. Further study will include much larger sample patients and verify our hypothesis. Other factors not included in this analysis, such as age of onset, illness duration, and prior antidepressant use, may influence the hypothalamus-related resting brain network in depression. In addition, and perhaps most critical, was a lack of data on medication history. Since the majority of subjects had long-term depression (average episode duration = 4.04 years), they were likely to have taken antidepressants prior to study baseline; this prior medication use would likely have had a greater influence on functional brain networks than would concurrent medications, if any relationship exists. These factors should be addressed in future studies.

**Conflict of Interests**

The authors declare that there is no conflict of interests regarding the publication of this paper.

**Authors’ Contribution**

Rui Yang and Hongbo Zhang contribute equally to this work.

**Acknowledgment**

This work was supported by the Natural Science Foundation of Shaanxi Province (2012J4028).

**References**

[1] WHO, *The Global Burden of Disease: 2004 Update*, WHO, 2008.
[2] A. T. Beck, *Depression: Causes and Treatment*, University of Pennsylvania Press, Philadelphia, Pa, USA, 1967.
[3] A. Mathews and C. MacLeod, “Cognitive vulnerability to emotional disorders,” *Annual Review of Clinical Psychology*, vol. 1, pp. 167–195, 2005.
[4] G. Parker, “Classifying depression: should paradigms lost be regained?” *American Journal of Psychiatry*, vol. 157, no. 8, pp. 1195–1203, 2000.
[5] J. Houenou, J. Frommberger, S. Carde et al., “Neuroimaging-based markers of bipolar disorder: evidence from two meta-analyses,” *Journal of Affective Disorders*, vol. 132, no. 3, pp. 344–355, 2011.
[6] P. E. Keck Jr, R. C. Kessler, and R. Ross, “Clinical and economic effects of unrecognized or inadequately treated bipolar disorder,” *Journal of Psychiatric Practice*, vol. 14, supplement 2, pp. 31–38, 2008.
[7] C. L. Bowden, “Strategies to reduce misdiagnosis of bipolar depression,” *Psychiatric Services*, vol. 52, no. 1, pp. 51–55, 2001.
[8] V. Lorenzetti, N. B. Allen, A. Fornito, and M. Yücel, “Structural brain abnormalities in major depressive disorder: a selective review of recent MRI studies,” *Journal of Affective Disorders*, vol. 117, no. 1-2, pp. 1–17, 2009.
[9] A. Anand, Y. Li, Y. Wang et al., “Activity and connectivity of brain mood regulating circuit in depression: a functional magnetic resonance study,” *Biological Psychiatry*, vol. 57, no. 10, pp. 1079–1088, 2005.
[10] M. L. Schölvinck, A. Maier, F. Q. Ye, J. H. Duy, and D. A. Leopold, “Neural basis of global resting-state fMRI activity,” *Proceedings of the National Academy of Sciences of the United States of America*, vol. 107, no. 22, pp. 10238–10243, 2010.
[11] J. S. Damoiseaux, S. A. R. B. Rombouts, F. Barkhof et al., “Consistent resting-state networks across healthy subjects,” *Proceedings of the National Academy of Sciences of the United States of America*, vol. 103, no. 37, pp. 13848–13853, 2006.
[12] C.-H. Liu, X. Ma, X. Wu et al., “Resting-state abnormal baseline brain activity in unipolar and bipolar depression,” *Neuroscience Letters*, vol. 516, no. 2, pp. 202–206, 2012.
[13] M. D. Greicius, B. H. Flores, V. Menon et al., “Resting-state functional connectivity in major depression: abnormally increased contributions from subgenual cingulate cortex and thalamus,” *Biological Psychiatry*, vol. 62, no. 5, pp. 429–437, 2007.
[14] Y. I. Sheline, J. L. Price, Z. Yan, and M. A. Mintun, “Resting-state functional MRI in depression unmasks increased connectivity.
between networks via the dorsal nexus,” *Proceedings of the National Academy of Sciences of the United States of America*, vol. 107, no. 24, pp. 11020–11025, 2010.

[15] M. A. Hofman and D. F. Swaab, “The human hypothalamus: comparative morphometry and photoperiodic influences,” *Progress in Brain Research*, vol. 93, pp. 133–149, 1992.

[16] R. Nieuwenhuys, J. Voogd, and C. van Huijzen, “Diencephalon: hypothalamus,” in *The Human Central Nervous System: A Synopsis and Atlas*, pp. 289–336, Springer, Berlin, Germany, 4th edition, 2008.

[17] S. M. Strakowski, M. P. DelBello, and C. M. Adler, “The functional neuroanatomy of bipolar disorder: a review of neuroimaging findings,” *Molecular Psychiatry*, vol. 10, no. 1, pp. 105–116, 2005.

[18] M. E. Sublette, M. A. Oquendo, and J. J. Mann, “Rational approaches to the neurobiologic study of youth at risk for bipolar disorder and suicide,” *Bipolar Disorders*, vol. 8, no. 5, pp. 526–542, 2006.

[19] D. A. Cousins, K. Butts, and A. H. Young, “The role of dopamine in bipolar disorder,” *Bipolar Disorders*, vol. 11, no. 8, pp. 787–806, 2009.

[20] J. L. Price and W. C. Drevets, “Neurocircuitry of mood disorders,” *Neuropsychopharmacology*, vol. 35, no. 1, pp. 192–216, 2010.

[21] D. F. Swaab, “Hypothalamic involvement in psychiatric disorders,” in *Handbook of Clinical Neurology*, M. J. Aminoff, F. Boller, and D. F. Swaab, Eds., vol. 80 of *The Human Hypothalamus: Basic and Clinical Aspects*, pp. 248–272, Elsevier, Amsterdam, 2003.

[22] G. L. Quirarte, B. Roozendaal, and J. L. McGaugh, “Glucocorticoid enhancement of memory storage involves noradrenergic activation in the basolateral amygdala,” *Proceedings of the National Academy of Sciences of the United States of America*, vol. 94, no. 25, pp. 14048–14053, 1997.

[23] B. Roozendaal, “Stress and memory: opposing effects of glucocorticoids on memory consolidation and memory retrieval,” *Neurobiology of Learning and Memory*, vol. 78, no. 3, pp. 578–595, 2002.

[24] E. Fuchs, B. Czéh, M. H. P. Kole, T. Michaelis, and P. J. Lucassen, “Alterations of neuroplasticity in depression: the hippocampus and beyond,” *European Neuropsychopharmacology*, vol. 14, no. 5, pp. S481–S490, 2004.

[25] C. B. Nemeroof, “The corticotropin-releasing factor (CRF) hypothesis of depression: new findings and new directions,” *Molecular Psychiatry*, vol. 1, no. 4, pp. 336–342, 1996.

[26] H. K. Manji, J. A. Quiroz, J. Sporn et al., “Enhancing neuronal excitability of principal basolateral amygdala neurons,” *NeuroImage*, vol. 53, no. 8, pp. 707–742, 2003.

[27] P. Brambilla, J. Perez, F. Barale, G. Schettini, and J. C. Soares, “GABAergic dysfunction in mood disorders,” *Molecular Psychiatry*, vol. 8, no. 8, pp. 721–737, 2003.

[28] P. Brambilla, A. Cipriani, M. Hotopf, and C. Barbui, “Side-effect profile of fluoxetine in comparison with other SSRIs, tricyclic and newer antidepressants: a meta-analysis of clinical trial data,” *Pharmacopsychiatry*, vol. 38, no. 2, pp. 69–77, 2005.

[29] M. Sala, F. Coppa, C. Cappucciati et al., “Antidepressants: their effects on cardiac channels, QT prolongation and Torsade de Pointes,” *Current Opinion in Investigational Drugs*, vol. 7, no. 3, pp. 256–263, 2006.

[30] H. Verdoux, M. Tournier, and B. Bégaud, “Pharmacoepidemiology of psychotropic drugs: examples of current research challenges on major public health issues,” *Epidemiologia e Psichiatria Sociale*, vol. 18, no. 2, pp. 107–113, 2009.

[31] M. B. Keller, P. W. Lavoi, T. I. Mueller et al., “Time to recovery, chronicity, and levels of psychopathology in major depression: a 5-year prospective follow-up of 431 subjects,” *Archives of General Psychiatry*, vol. 49, no. 10, pp. 809–816, 1992.

[32] A. Cipriani, P. Brambilla, T. Furukawa et al., “Fluoxetine versus other types of pharmacotherapy for depression,” *Cochrane Database of Systematic Reviews*, no. 4, Article ID CD004185, 2005.

[33] S. Patten, A. Cipriani, P. Brambilla, M. Nosè, and C. Barbui, “International dosage differences in fluoxetine clinical trials,” *Canadian Journal of Psychiatry*, vol. 50, no. 1, pp. 31–38, 2005.

[34] M. Slade, M. Amering, and L. Oades, “Recovery: an international perspective,” *Epidemiologia e Psichiatria Sociale*, vol. 17, no. 2, pp. 128–137, 2008.

[35] T. S. Braver, J. D. Cohen, L. E. Nystrom, J. Jonides, E. E. Smith, and D. C. Noll, “A parametric study of prefrontal cortex involvement in human working memory,” *NeuroImage*, vol. 5, no. 1, pp. 49–62, 1997.

[36] M. D’Esposito, B. R. Postle, and B. Rypma, “Prefrontal cortical contributions to working memory: evidence from event-related fMRI studies,” *Experimental Brain Research*, vol. 133, no. 1, pp. 3–11, 2000.

[37] G. Rajkowska, J. J. Miguel-Hidalgo, J. Wei et al., “Morphometric evidence for neuronal and glial prefrontal cell pathology in major depression,” *Biological Psychiatry*, vol. 45, no. 9, pp. 1085–1098, 1999.

[38] A. J. Thomas, R. Perry, R. N. Kalaria, A. Oakley, W. McMeekin, and J. T. O’Brien, “Neuropathological evidence for ischemia in the white matter of the dorsolateral prefrontal cortex in late-life depression,” *International Journal of Geriatric Psychiatry*, vol. 18, no. 1, pp. 7–13, 2003.

[39] G. S. Alexopoulos, B. S. Meyers, R. C. Young, T. Kakuma, D. Silbersweig, and M. Charlson, “Clinically defined vascular depression,” *American Journal of Psychiatry*, vol. 154, no. 4, pp. 562–565, 1997.

[40] K. R. R Krishnan, J. C. Hays, and D. G. Blazer, “MRI-defined vascular depression,” *American Journal of Psychiatry*, vol. 154, no. 4, pp. 497–501, 1997.

[41] F. Biver, S. Goldman, V. Delvenne et al., “Frontal and parietal metabolic disturbances in unipolar depression,” *Biological Psychiatry*, vol. 36, no. 6, pp. 381–388, 1994.

[42] I. I. Galyanker, J. Cai, F. Ongseng, H. Finestone, E. Dutta, and D. Sereni, “Hypofrontality and negative symptoms in major depressive disorder,” *Journal of Nuclear Medicine*, vol. 39, no. 4, pp. 608–612, 1998.

[43] S. Duvardi and D. Pare, “Glucocorticoids enhance the excitability of principal basolateral amygdala neurons,” *Journal of Neuroscience*, vol. 27, no. 16, pp. 4482–4491, 2007.

[44] L. Jacobson and R. Sapolsky, “The role of the hippocampus in feedback regulation of the hypothalamic-pituitary-adrenocortical axis,” *Endocrine Reviews*, vol. 12, no. 2, pp. 118–134, 1991.

[45] J. P. Herman, C. M. F. Prewitt, and W. E. Cullinan, “Neuronal circuit regulation of the hypothalamo-pituitary-adrenocortical stress axis,” *Critical Reviews in Neurobiology*, vol. 10, no. 3–4, pp. 371–394, 1996.

[46] C. Belzung and E. Billette de Villemeur, “The design of new antidepressants: conformational models help? A first attempt using...
a model of the hippocampal control over the HPA-axis based on a review from the literature,” *Behavioural Pharmacology*, vol. 21, no. 8, pp. 677–689, 2010.

[47] Y. M. Ulrich-Lai and J. P. Herman, “Neural regulation of endocrine and autonomic stress responses,” *Nature Reviews Neuroscience*, vol. 10, pp. 397–409, 2009.

[48] W. C. Drevets, J. Savitz, and M. Trimble, “The subgenual anterior cingulate cortex in mood disorders,” *CNS Spectrum*, vol. 13, no. 8, pp. 663–681, 2008.

[49] M. D. Greicius, “Functional connectivity in the resting brain: a network analysis of the default mode hypothesis,” *Proceedings of the National Academy of Sciences of the United States of America*, vol. 100, no. 1, pp. 253–258, 2003.

[50] M. S. Korgaonkar, “Loss of white matter integrity in major depressive disorder: evidence using tract-based spatial statistical analysis of diffusion tensor imaging,” *Human Brain Mapping*, vol. 32, no. 12, pp. 2161–2171, 2011.

[51] D. Ongür and J. L. Price, “The organization of networks within the orbital and medial prefrontal cortex of rats, monkeys and humans,” *Cerebral Cortex*, vol. 10, no. 3, pp. 206–219, 2000.

[52] F. A. Middleton and P. L. Strick, “Cerebellar projections to the prefrontal cortex of the primate,” *Journal of Neuroscience*, vol. 21, pp. 700–712, 2001.

[53] J. D. Schmahmann, “Disorders of the cerebellum: ataxia, dysmetria of thought, and the cerebellar cognitive affective syndrome,” *Journal of Neuropsychiatry & Clinical Neurosciences*, vol. 16, pp. 367–378, 2004.